# WuXi XDC

Source: https://onco.cc/companies/wuxi-xdc/  
OnCo record `wuxi-xdc` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

WuXi XDC is the largest dedicated ADC CDMO, spun out of WuXi Biologics and listed in Hong Kong in 2023; it is exposed to US BIOSECURE Act politics.

## Summary

WuXi XDC, based in Wuxi and listed in Hong Kong as 2268.HK, is the largest dedicated antibody-drug conjugate CDMO, spun out of WuXi Biologics and listed in 2023, and it is exposed to the politics of the US BIOSECURE Act. It offers integrated antibody, payload-linker, conjugation and fill-finish services, a large share of the world's clinical ADCs are made there, and it is building a Singapore site to diversify from China. OnCo links it to ADC bioconjugation manufacturing and payload-linker synthesis and to the BIOSECURE Act term. Whether Western sponsors move ADC manufacturing out of China under political pressure, and whether alternative capacity exists to receive it, is the open question. The BIOSECURE Act page carries the policy detail.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: supporting
- HQ: Wuxi
- Type: cro-services
- Website: https://www.wuxixdc.com
- Ticker: 2268.HK

## Sources

- Official website: https://www.wuxixdc.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [ADC bioconjugation manufacturing (CDMOs)](https://onco.cc/technologies/adc-cdmo-manufacturing/), [Payload-linker synthesis (high-potency API)](https://onco.cc/technologies/high-potency-payload-synthesis/), [The ADC supply chain (antibody, payload-linker, conjugation, fill)](https://onco.cc/technologies/adc-supply-chain/)
- terms: [BIOSECURE Act](https://onco.cc/terms/biosecure-act/)

---
JSON: https://onco.cc/api/v1/entities/wuxi-xdc.json